Petráš Marek, Lesná Ivana Králová, Dáňová Jana, Čelko Alexander M
Department of Epidemiology and Biostatistics, Charles University in PragueThird Faculty of Medicine, 100 00 Prague, Czech Republic.
Laboratory for Atherosclerosis Research, Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic.
Vaccines (Basel). 2020 Mar 27;8(2):150. doi: 10.3390/vaccines8020150.
While the weight of epidemiological evidence does not support a causal link with influenza vaccination evaluated over the last 30 years, Guillain-Barré syndrome (GBS) has been considered a vaccine-associated adverse event of interest since 1976. To investigate the existence of GBS risk after vaccination against seasonal influenza, a systematic review and meta-analysis have been conducted based on 22 eligible epidemiological studies from 1981 to 2019 reporting 26 effect sizes (ESs) in different influenza seasons. The primary result of our meta-analysis pointed to no risk of vaccine-associated GBS, as documented by a pooled ES of 1.15 (95% CI: 0.97-1.35). Conversely, an obvious high risk of GBS was observed in patients with previous influenza-like illness (ILI), as demonstrated by a pooled ES of 9.6 (95% CI: 4.0-23.0) resulting from a supplementary analysis. While the meta-analysis did not confirm the putative risk of vaccine-associated GBS suggested by many epidemiological studies, vaccination against seasonal influenza reduced the risk of developing ILI-associated GBS by about 88%. However, to obtain strong evidence, more epidemiological studies are warranted to establish a possible coincidence between vaccination and ILI prior to GBS onset.
虽然过去30年评估的流行病学证据权重不支持与流感疫苗接种存在因果关系,但自1976年以来,吉兰-巴雷综合征(GBS)一直被视为一种与疫苗相关的关注不良事件。为了调查季节性流感疫苗接种后GBS风险的存在情况,基于1981年至2019年的22项符合条件的流行病学研究进行了系统评价和荟萃分析,这些研究报告了不同流感季节的26个效应量(ESs)。我们荟萃分析的主要结果表明不存在疫苗相关GBS风险,合并效应量为1.15(95%CI:0.97 - 1.35)证明了这一点。相反,在既往有流感样疾病(ILI)的患者中观察到明显的GBS高风险,补充分析得出的合并效应量为9.6(95%CI:4.0 - 23.0)证明了这一点。虽然荟萃分析未证实许多流行病学研究所表明的疫苗相关GBS假定风险,但季节性流感疫苗接种使ILI相关GBS的发生风险降低了约88%。然而,为了获得有力证据,需要更多的流行病学研究来确定GBS发病前疫苗接种与ILI之间可能的巧合关系。